UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 174

Sortiert nach

Combining reproductive endocrinology and ROC analysis to identify changes with sex, age, and pregnancy status in Amazon River dolphins Inia geoffrensis

Endangered species research, 2024

2024

Volltextzugriff (PDF)

Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients

Cancer, 2001-10, Vol.92 (7), p.1759-1768

2001

Volltextzugriff (PDF)

Abstract OT3-05-03: POLARIS: Palbociclib (P) in hormone receptor-positive (HR+) advanced breast cancer: A prospective multicenter noninterventional study

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT3-05-03-OT3-05-03

2018

Volltextzugriff (PDF)

Abstract P3-04-02: Molecular analysis of breast cancers from individuals with hereditary cancer syndromes secondary to mutations in BRCA1, BRCA2, ATM, CHEK2, and PALB2

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P3-P3-04-02

2018

Volltextzugriff (PDF)

Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.485-493

1999

Volltextzugriff (PDF)

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS6-07-GS6-07

2018

Volltextzugriff (PDF)

Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil

Annals of oncology, 2002-03, Vol.13 (3), p.484-485

2002

Volltextzugriff (PDF)

Abstract OT1-03-16: EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT1-03-16-OT1-03-16

2016

Volltextzugriff (PDF)

Strategies for improving outcomes in the acute management of ischemic stroke in rural emergency departments: a quality improvement initiative in the Stroke Belt

Open access emergency medicine, 2018-01, Vol.10, p.53-59

2018

Volltextzugriff (PDF)

The Role of Capecitabine, an Oral, Enzymatically Activated Fluoropyrimidine, in the Treatment of Metastatic Breast Cancer

The oncologist (Dayton, Ohio), 2001-01, Vol.6 (1), p.56-64

Blum, Joanne L.

2001

Volltextzugriff (PDF)

P5-19-08: Pooled Analysis of Individual Patient Data from Capecitabine Monotherapy Clinical Trials in Anthracycline-/Taxane-Pretreated Locally Advanced or Metastatic Breast Cancer (LA/MBC)

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-19-08

2011

Volltextzugriff (PDF)

Abstract P6-13-01: Impact of the Number of Prior Chemotherapy Regimens on Overall Survival (OS) among Subjects with Locally Recurrent or Metastatic Breast Cancer Treated with Eribulin Mesylate: Results from the Phase III EMBRACE Study

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P6-P6-13-01

2010

Volltextzugriff (PDF)

Selective Interactions of Krüppel-like Factor 9/Basic Transcription Element-binding Protein with Progesterone Receptor Isoforms A and B Determine Transcriptional Activity of Progesterone-responsive Genes in Endometrial Epithelial Cells

The Journal of biological chemistry, 2003-06, Vol.278 (24), p.21474-21482

2003

Volltextzugriff (PDF)

Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier

Cancer research (Chicago, Ill.), 1998-08, Vol.58 (15), p.3237-3242

1998

Volltextzugriff (PDF)

Relevance and Safety of Telomerase for Human Tissue Engineering

Proceedings of the National Academy of Sciences - PNAS, 2006-02, Vol.103 (8), p.2500-2505

2006

Volltextzugriff (PDF)

OT3-01-16: A Phase 2 Study of Ridaforolimus (RIDA) and Dalotuzumab (DALO) in Estrogen Receptor Positive (ER+) Breast Cancer

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.OT3-01-16-OT3-01-16

2011

Volltextzugriff (PDF)

Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-16-04

2013

Volltextzugriff (PDF)

Abstract OT2-6-13: A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.OT2-6-13-OT2-6-13

2013

Volltextzugriff (PDF)

Phosphorylation and binding of AUF1 to the 3'-untranslated region of cardiomyocyte SERCA2a mRNA

American journal of physiology. Heart and circulatory physiology, 2005-12, Vol.289 (6), p.H2543-H2550

2005

Volltextzugriff (PDF)

P5-18-09: The Incidence of Febrile Neutropenia in the First Course of Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide with or without Pegfilgrastim

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-18-09

2011

Volltextzugriff (PDF)

Guidelines for systemic therapy of early stage breast cancer

Breast cancer research and treatment, 1997-05, Vol.43 (3), p.259-276

1997

Volltextzugriff (PDF)

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.S4-S4-2

2010

Volltextzugriff (PDF)

Direct interaction of the Krüppel-like family (KLF) member, BTEB1, and PR mediates progesterone-responsive gene expression in endometrial epithelial cells

Endocrinology (Philadelphia), 2002-01, Vol.143 (1), p.62-73

2002

Volltextzugriff (PDF)

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

Annals of oncology, 2001-05, Vol.12 (5), p.605-614

2001

Volltextzugriff (PDF)

Efficacy of pre-treatment with lufenuron for the prevention of Microsporum canis infection in a feline direct topical challenge model

Veterinary dermatology, 2004-12, Vol.15 (6), p.357-362

2004

Volltextzugriff (PDF)

1 – 25 von 174

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(143)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(155)
Life Sciences & Biomedicine
(112)
Biological And Medical Sciences
(66)
Female
(60)
Humans
(59)
Male
(42)
Animals
(40)
Medical Sciences
(40)
Physical Sciences
(33)
Fundamental And Applied Biological Sciences. Psychology
(29)
Adult
(27)
Middle Aged
(25)
Oncology
(25)
Pharmacology. Drug Treatments
(24)
Physics
(21)
Aged
(19)
Rats
(18)
Antineoplastic Agents
(15)
Chemotherapy
(15)
Endocrinology & Metabolism
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Combining reproductive endocrinology and ROC analysis to identify changes with sex, age, and pregnancy status in Amazon River dolphins Inia geoffrensis

Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients

Abstract OT3-05-03: POLARIS: Palbociclib (P) in hormone receptor-positive (HR+) advanced breast cancer: A prospective multicenter noninterventional study

Abstract P3-04-02: Molecular analysis of breast cancers from individuals with hereditary cancer syndromes secondary to mutations in BRCA1, BRCA2, ATM, CHEK2, and PALB2

Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil

Abstract OT1-03-16: EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer

Strategies for improving outcomes in the acute management of ischemic stroke in rural emergency departments: a quality improvement initiative in the Stroke Belt

The Role of Capecitabine, an Oral, Enzymatically Activated Fluoropyrimidine, in the Treatment of Metastatic Breast Cancer

P5-19-08: Pooled Analysis of Individual Patient Data from Capecitabine Monotherapy Clinical Trials in Anthracycline-/Taxane-Pretreated Locally Advanced or Metastatic Breast Cancer (LA/MBC)

Abstract P6-13-01: Impact of the Number of Prior Chemotherapy Regimens on Overall Survival (OS) among Subjects with Locally Recurrent or Metastatic Breast Cancer Treated with Eribulin Mesylate: Results from the Phase III EMBRACE Study

Selective Interactions of Krüppel-like Factor 9/Basic Transcription Element-binding Protein with Progesterone Receptor Isoforms A and B Determine Transcriptional Activity of Progesterone-responsive Genes in Endometrial Epithelial Cells

Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier

Relevance and Safety of Telomerase for Human Tissue Engineering

OT3-01-16: A Phase 2 Study of Ridaforolimus (RIDA) and Dalotuzumab (DALO) in Estrogen Receptor Positive (ER+) Breast Cancer

Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer

Abstract OT2-6-13: A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer

Phosphorylation and binding of AUF1 to the 3'-untranslated region of cardiomyocyte SERCA2a mRNA

P5-18-09: The Incidence of Febrile Neutropenia in the First Course of Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide with or without Pegfilgrastim

Guidelines for systemic therapy of early stage breast cancer

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

Direct interaction of the Krüppel-like family (KLF) member, BTEB1, and PR mediates progesterone-responsive gene expression in endometrial epithelial cells

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

Efficacy of pre-treatment with lufenuron for the prevention of Microsporum canis infection in a feline direct topical challenge model

Suchergebnisse filtern